Global Cerebral Palsy Treatment Market Report to 2030 –

Dublin, May 16, 2022 (GLOBE NEWSWIRE) — The report “Cerebral Palsy Treatment Market by Drug Type, Disease Type, Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2030” has been added to from ResearchAndMarkets.com offer.

Global Cerebral Palsy Treatment Market was valued at USD 3166.82 Million in 2020 and is projected to reach USD 4365.01 Million by 2030, registering a CAGR of 3.3% from 2021 to 2030.

Cerebral palsy is a group of disorders that affect a person’s ability to move around and maintain balance and posture. Cerebral palsy is the most common motor disability in children. Cerebral palsy is caused by abnormal brain development or damage to the developing brain that affects a person’s ability to control their muscles.

Patients with cerebral palsy require lifelong care with a medical care team. Although there is no cure for cerebral palsy, there are various treatments like medications, therapies, surgeries and other treatments. Medications include muscle or nerve injections and oral muscle relaxants. The main therapies include physical therapies, occupational therapies, speech and language therapies, and recreational therapies.

Factors that are driving the growth of the global cerebral palsy treatment market include the upsurge in the prevalence of cerebral palsy, increasing attention to technological advancements in healthcare coupled with increasing availability of novel cerebral palsy drugs , increasing research and development skills, government initiatives to promote the awareness and growing addiction to drugs are the major factors prevailing in the growth of the global cerebral palsy treatment market.

However, the high costs associated with the drugs are expected to create obstacles for the growth of the cerebral palsy treatment market. Additionally, drug-associated side effects such as drowsiness, depression, headache, lethargy, confusion, dizziness, and lack of awareness in backward and underdeveloped economies cause Barriers in Cerebral Palsy Treatment Market.

Various initiatives have been taken by the government to encourage regulatory affairs to gain approvals for new drugs and insurance policies that create lucrative opportunities in the cerebral palsy treatment market.

The report segments the market on the basis of drug type, disease type, distribution channel and region. Depending on the type of drug, it is classified into anticholinergics, anticonvulsants, antidepressants and others. Depending on the type of disease, it is classified into spastic cerebral palsy, dyskinetic cerebral palsy, ataxic cerebral palsy, and mixed cerebral palsy. Based on the distribution channel, the market is divided into hospital pharmacies, retail stores and pharmacies, and online providers. Based on region, it is analyzed across North America, Europe, Asia-Pacific and LAMEA.

Regionally, this market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the largest market share in the cerebral palsy treatment market in 2020 and is expected to maintain its dominance throughout the forecast period. This is mainly attributed to a significant increase in investments as well as partnerships and collaborations.

Business expansion is the key strategy adopted by market players. The report provides a comprehensive analysis of the key players operating in the global cerebral palsy treatment market. Key companies profiled in the report are Merz Pharmaceuticals, LLC., Pfizer Inc., Teva Pharmaceuticals, Bayer AG, Johnson & Johnson, GlaxoSmithKline plc., Novartis, AbbVie Inc., Par Pharmaceutical, Allergan plc., Lannett Company, Inc.

Key Benefits

  • The report provides an in-depth analysis of the global cerebral palsy treatment market size along with current trends and future estimates to elucidate impending investment pockets.
  • It offers an analysis of the market from 2021 to 2030, which is expected to enable stakeholders to capitalize on the existing opportunities in the market.
  • Comprehensive region analysis helps in understanding the regional market, aids in strategic business planning and determines existing opportunities
  • Profiles and growth strategies of key players are thoroughly analyzed to understand the competitive prospects for the growth of the global Cerebral Palsy Treatment market

Main topics covered:

Chapter 1 Introduction

Chapter 2: Executive Summary

Chapter 3: Market Landscape
3.1. Market definition and scope
3.2. Main findings
3.2.1. Best Investment Pockets
3.2.2. Best Winning Strategies
3.3. Porter’s Five Forces Analysis
3.4. Positioning of the best player, 2020
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Increased incidences of cerebral palsy
3.5.1.2. Increase in investments by key player
3.5.2. Detention
3.5.2.1. Medication-Associated Side Effects
3.5.3. Opportunity
3.5.3.1. Government initiatives for regulatory approvals
3.6. Analysis of the impact of Covid-19 on the cerebral palsy treatment market

Chapter 4: Cerebral Palsy Treatment Market, By Drug Type
4.1. Insight
4.1.1. Market size and forecast
4.2. Anticholinergics
4.2.1. Market size and forecast, by region
4.2.2. Market analysis, by country
4.3. Anticonvulsants
4.3.1. Market size and forecast, by region
4.3.2. Market analysis, by country
4.4. Antidepressants
4.4.1. Market size and forecast, by region
4.4.2. Market analysis, by country
4.5. Others
4.5.1. Market size and forecast, by region
4.5.2. Market analysis, by country

Chapter 5: Cerebral Palsy Treatment Market, By Disease Type
5.1. Insight
5.1.1. Market size and forecast
5.2. Spastic cerebral palsy
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Dyskinetic cerebral palsy
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Ataxic cerebral palsy
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.5. Mixed cerebral palsy
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country

Chapter 6: Cerebral Palsy Treatment Market, By Distribution Channel
6.1. Insight
6.1.1. Market size and forecast
6.2. Hospital pharmacy
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Retail Store and Pharmacy
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
6.4. Online Suppliers
6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country

Chapter 7: Cerebral Palsy Treatment Market, By Region

Chapter 8: Company Profiles
8.1. Abbvie Inc.
8.1.1. Company presentation
8.1.2. Company overview
8.1.3. Operating business areas
8.1.4. Product portfolio
8.1.5. Company Performance
8.1.6. Key strategic moves and developments
8.2. Bayer AG
8.2.1. Company presentation
8.2.2. Company overview
8.2.3. Operating business areas
8.2.4. Product portfolio
8.2.5. Company performance
8.3. GlaxoSmithKline plc.
8.3.1. Company presentation
8.3.2. Company overview
8.3.3. Operating business areas
8.3.4. Product portfolio
8.3.5. Company performance
8.4. Johnsons and Johnsons
8.4.1. Company presentation
8.4.2. Company overview
8.4.3. Operating business areas
8.4.4. Product portfolio
8.4.5. Company Performance
8.4.6. Key strategic moves and developments
8.5. Lannet Company, Inc.
8.5.1. Company presentation
8.5.2. Company overview
8.5.3. Operating business areas
8.5.4. Product portfolio
8.5.5. Company performance
8.5.6. Key strategic moves and developments
8.6. Merz Pharmaceuticals, LLC.
8.6.1. Company presentation
8.6.2. Company overview
8.6.3. Operating business areas
8.6.4. Product portfolio
8.6.5. Key strategic moves and developments
8.7. Novartis
8.7.1. Company presentation
8.7.2. Company overview
8.7.3. Operating business areas
8.7.4. Product portfolio
8.7.5. Company Performance
8.8. By Pharmaceuticals
8.8.1. Company presentation
8.8.2. Company overview
8.8.3. Operating business areas
8.8.4. Product portfolio
8.9. Pfizer, Inc.
8.9.1. Company presentation
8.9.2. Company overview
8.9.3. Operating business areas
8.9.4. Product portfolio
8.9.5. Company performance
8.10. Teva Pharmaceutical Industries Limited.
8.10.1. Company presentation
8.10.2. Company overview
8.10.3. Operating business areas
8.10.4. Product portfolio
8.10.5. Company performance

For more information about this report visit https://www.researchandmarkets.com/r/yqt38e

  • Global cerebral palsy treatment market


        

About Antoine L. Cassell

Check Also

IMU-838 treatment associated with low rate of confirmed disability worsening in relapsing MS

Recently reported interim data from the Phase 2 EMPhASIS trial (NCT03846219) of Immunic’s investigational agent, …